{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"13.8","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. DoR was defined as the time from the date of first documented response (CR or PR that was subsequently confirmed) until the date of documented progression (PD) or death in the absence of disease progression (by investigator assessment).","dispersionType":"95% Confidence Interval","groups":[{"description":"Pre-treated EGFR T790M mutation positive (by central testing) population. Dose groups were expanded to include more patients.","id":"OG000","title":"Dose Expansion"}],"paramType":"MEDIAN","populationDescription":"All pre-treated EGFR T790M mutation positive (by central testing) patients who received at least one dose of AZD9291.","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 21 months (at time of analysis)","title":"Duration of Response (DoR) for Dose Expansion Population","type":"SECONDARY","unitOfMeasure":"months"}